Skip to main content
    • Aa
    • Aa

Aspects of communication in Alzheimer's disease: clinical features and treatment options

  • Michael Woodward (a1)

Background: During the course of Alzheimer's disease (AD), cognitive processes, including language and communication, become increasingly impaired. The aim of this review was to highlight the impact of communication deficits in AD, and discuss the need for effective treatments.

Method: PubMed was searched for studies relating to language and communication in AD. The publications identified were used as a basis for the commentary in this paper. Studies relating to the clinical effectiveness of pharmacological treatment for language and communication issues were identified systematically.

Results: Communication deficits are common in AD. From the earliest disease stage, the patient's capacity for communication declines as problems develop with the use of language and all aspects of functional communication. There is a loss of the ability to communicate thoughts and needs, and it becomes increasingly difficult to interact socially and sustain personal relationships with caregivers, family, and friends. It is unsurprising that patients become frustrated at their loss of self-expression, and studies have demonstrated that impaired communication is strongly linked with the development of significant behavioral concerns. Overall, poor communication contributes to caregiver strain, and adds notably to the burden of disease. Clinical data and post-hoc analyses provide preliminary indications that anti-AD therapies (memantine and the cholinesterase inhibitors, ChEIs) and non-pharmacological cognitive–linguistic stimulation techniques may be helpful in addressing communication difficulties.

Conclusions: The capacity to treat or slow the progression of communication deficits in AD would prolong patient independence, and have a profound impact on the quality of life of patients and caregivers. The use of pharmacological (anti-AD therapies) and non-pharmacological (cognitive–linguistic stimulation) treatments may be useful management methods and warrant further investigation.

Corresponding author
Correspondence should be addressed to: Michael Woodward, Associate Professor, Aged Care Services, Heidelberg Repatriation Hospital, Austin Health, 300 Waterdale Road, Heidelberg West, Victoria 3081, Australia. Phone: +61-3-9496-2185; Fax: +61-3-9496-2613. Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

L. J. Altmann and J. S. McClung (2008). Effects of semantic impairment on language use in Alzheimer's disease. Seminars in Speech and Language, 29, 1831.

S. Arkin (2007). Language-enriched exercise plus socialization slows cognitive decline in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 22, 6277.

N. Bassil , P. Thaipisuttikul and G. T. Grossberg (2010). Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 11, 17651771.

K. A. Bayles and E. S. Kim (2003). Improving the functioning of individuals with Alzheimer's disease: emergence of behavioral interventions. Journal of Communication Disorders, 36, 327343.

K. A. Bayles , C. K. Tomoeda and M. W. Trosset (1992). Relation of linguistic communication abilities of Alzheimer's patients to stage of disease. Brain and Language, 42, 454472.

J. Birks (2009). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD005593.

M. Blair , C. A. Marczinski , N. Davis-Faroque and A. Kertesz (2007). A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. Journal of the International Neuropsychological Society, 13, 237245.

M. Brotons and S. M. Koger (2000). The impact of music therapy on language functioning in dementia. Journal of Music Therapy, 37, 183195.

S. B. Chapman , M. F. Weiner , A. Rackley , L. S. Hynan and J. Zientz (2004). Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. Journal of Speech, Language, and Hearing Research, 47, 11491163.

S. Cosentino , N. Scarmeas , S. M. Albert and Y. Stern (2006). Verbal fluency predicts mortality in Alzheimer's disease. Cognitive and Behavioral Neurology, 19, 123129.

M. Cotelli et al. (2011). Improved language performance in Alzheimer disease following brain stimulation. Journal of Neurology, Neurosurgery & Psychiatry, 82, 794797.

I. A. M. de Carvalho and L. L. Mansur (2008). Validation of ASHA-FACS functional assessment of communication skills for Alzheimer's disease population. Alzheimer Disease & Associated Disorders, 22, 375381.

M. Egan , D. Bérubé , G. Racine , C. Leonard and E. Rochon (2010). Methods to enhance verbal communication between individuals with Alzheimer's disease and their formal and informal caregivers: a systematic review. International Journal of Alzheimer's Disease, doi:10.4061/2010/906818.

M. R. Farlow , J. L. Cummings , J. T. Olin and X. Meng (2010). Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 25, 347352.

S. Ferris et al. (2009a). Severe impairment battery language scale: a language-assessment tool for Alzheimer's disease patients. Alzheimer's & Dementia, 5, 375379.

S. H. Ferris et al. (2011). Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research & Therapy, 3, 22.

K. E. Forbes-McKay and A. Venneri (2005). Detecting subtle spontaneous language decline in early Alzheimer's disease with a picture description task. Neurological Sciences, 26, 243254.

P. S. Foster et al. (2012). Acetylcholinesterase inhibitors reduce spreading activation in dementia. Neuropsychologia, 50, 20932099.

S. V. Frankfort et al. (2007). Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiology and Drug Safety, 16, 545551.

D. Fromm and A. L. Holland (1989). Functional communication in Alzheimer's disease. Journal of Speech and Hearing Disorders, 54, 535540.

J. Georges , S. Jansen , J. Jackson , A. Meyrieux , A. Sadowska and M. Selmes (2008). Alzheimer's disease in real life – the dementia carer's survey. International Journal of Geriatric Psychiatry, 23, 546551.

G. Glosser , M. J. Wiley and E. J. Barnoski (1998). Gestural communication in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 20, 113.

G. T. Grossberg , F. A. Schmitt , X. Meng , S. Tekin and J. Olin (2010). Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 25, 627633.

P. M. Hendryx-Bedalov (2000). Alzheimer's dementia. Coping with communication decline. Journal of Gerontological Nursing, 26, 2024.

T. Hopper (2001). Indirect interventions to facilitate communication in Alzheimer's disease. Seminars in Speech and Language, 22, 305315.

N. Mahendra (2001). Direct interventions for improving the performance of individuals with Alzheimer's disease. Seminars in Speech and Language, 22, 291303.

N. Mahendra and S. Arkin (2003). Effects of four years of exercise, language, and social interventions on Alzheimer discourse. Journal of Communication Disorders, 36, 395422.

P. Mecocci , A. Bladstrom and K. Stender (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry, 24, 532538.

J. B. Orange and E. B. Ryan (2000). Alzheimer's disease and other dementias. Implications for physician communication. Clinics in Geriatric Medicine, 16, 153173.

L. J. Phillips , S. A. Reid-Arndt and Y. Pak (2010). Effects of a creative expression intervention on emotions, communication, and quality of life in persons with dementia. Nursing Research, 59, 417425.

N. Pomara , B. R. Ott , E. Peskind and E. M. Resnick (2007). Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer's Disease and Associated Disorders, 21, 6064.

D. Potkins et al. (2003). Language impairment in dementia: impact on symptoms and care needs in residential homes. International Journal of Geriatric Psychiatry, 18, 10021006.

J. A. Powell , M. A. Hale and A. J. Bayer (1995). Symptoms of communication breakdown in dementia: carers’ perceptions. European Journal of Disorders of Communication, 30, 6575.

B. Reisberg et al. (2003). Memantine in moderate-to-severe Alzheimer's disease. The New England Journal of Medicine, 348, 13331341.

M. Y. Savundranayagam , M. L. Hummert and R. J. Montgomery (2005). Investigating the effects of communication problems on caregiver burden. Journals of Gerontology, Series B, 60, S48S55.

F. A. Schmitt , C. H. van Dyck , C. H. Wichems , J. T. Olin and Memantine MEM-MD-02 Study Group (2006). Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease & Associated Disorders, 20, 255262.

R. M. Tappen , C. L. Williams , C. Barry and D. Disesa (2002). Conversation intervention with Alzheimer's patients: increasing the relevance of communication. Clinical Gerontology, 24, 6375.

P. N. Tariot et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317324.

E. G. Visch Brink , W. Van Rhee Temme , T. Rietveld , J. W. Krulder , F. Van Harskamp and T. J. Van der Cammen (2009). Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine. Journal of Nutrition Health and Aging, 13, 3438.

M. F. Weiner , K. E. Neubecker , M. E. Bret and L. S. Hynan (2008). Language in Alzheimer's disease. Journal of Clinical Psychiatry, 69, 12231227.

D. Weintraub , M. Somogyi and X. Meng (2011). Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. American Journal of Alzheimer's Disease and Other Dementias, 26, 443449.

C. L. Williams (2011). What spouse caregivers know about communication in Alzheimer's disease: development of the AD Communication Knowledge Test. Issues in Mental Health Nursing, 32, 2834.

B. Winblad , R. W. Jones , Y. Wirth , A. Stöffler and H. J. Möbius (2007). Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders, 24, 2027.

M. Woodward et al. (2010). Differentiating the frontal variant of Alzheimer's disease. International Journal of Geriatric Psychiatry, 25, 732738.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *